AstraZeneca's Tagrisso shows 'encouraging' results in leptomeningeal disease

6 June 2016
astrazeneca-large

CHICAGO: Anglo-Swedish drugmaker AstraZeneca has released 'encouraging' early research data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease at the American Society of Clinical Oncology (ASCO) annual meeting.

LM is a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC),  where cancer cells spread to the cerebrospinal fluid (CSF).

The updated BLOOM Phase I data, presented at ASCO on Monday, reveals that irrespective of T790M status of patients, osimertinib led to a change in MRI signal intensity, which is indicative of a reduction in central nervous system (CNS) lesions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical